Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Ibudilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 154Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Medicinova Completes Patient Enrollment In Combat-Als Trial
    Medicinova Completes Patient Enrollment In Combat-Als Trial

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153885/7767/en/MediciNova-Announces-Completion-of-Patient-Enrollment-in-COMBAT-ALS-Phase-2b-3-Clinical-Trial-of-MN-166-ibudilast.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    MediciNova Presents COMBAT-ALS Trial Poster at 36th ALS/MND
    MediciNova Presents COMBAT-ALS Trial Poster at 36th ALS/MND

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150738/7767/en/MediciNova-Announces-Poster-Presentation-of-COMBAT-ALS-Clinical-Trial-at-the-36th-International-Symposium-on-ALS-MND.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
    MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

    26 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/26/3139673/7767/en/MediciNova-Achieves-Enrollment-in-COMBAT-ALS-Clinical-Trial.html

    GLOBENEWSWIRE
    26 Aug 2025
    Share Share
    MediciNova Updates Ph 2/3 COMBAT-ALS Trial at ALS/MND Symposium
    MediciNova Updates Ph 2/3 COMBAT-ALS Trial at ALS/MND Symposium

    06 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/05/2992777/7767/en/MediciNova-Presents-Study-Update-and-Interim-Analysis-of-Phase-2-3-Clinical-Trial-of-MN-166-ibudilast-in-ALS-COMBAT-ALS-Clinical-Trial-at-the-35th-International-Symposium-on-ALS-MN.html

    GLOBENEWSWIRE
    06 Dec 2024
    Share Share
    MediciNova's MN-166 Abstract Accepted For Poster Presentation
    MediciNova's MN-166 Abstract Accepted For Poster Presentation

    09 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2943304/7767/en/MediciNova-Announces-Abstract-Regarding-MN-166-ibudilast-in-COMBAT-ALS-Clinical-Trial-Accepted-for-Poster-Presentation-at-the-35th-International-Symposium-on-ALS-MND.html

    GLOBENEWSWIRE
    09 Sep 2024
    Share Share
    MediciNova's MN-166 in COMBAT-ALS Study to Present at NEALS 2024 Meeting
    MediciNova's MN-166 in COMBAT-ALS Study to Present at NEALS 2024 Meeting

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2940160/7767/en/MediciNova-Announces-Acceptance-of-Abstract-Regarding-MN-166-ibudilast-in-COMBAT-ALS-Clinical-Trial-for-Presentation-at-the-2024-Annual-NEALS-Northeast-Amyotrophic-Lateral-Sclerosi.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share